Riociguat is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat was developed by Bayer Aktiengesellschaft.
The API has now reached off-patent status, after being launched in 2013.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Riociguat was exported from India in 2023 , with an average price over the period of $42836 /kg.
The key suppliers were MSN Laboratories, with a focus on markets in Europe.

For enquiries regarding more detailed trade data of Riociguat and many others, contact info@pharmacheminvestor.com